Jason Leider
Internal Medicine · Bronx, NYNPI 1417035791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $543,371 of the $694,053 with a category attached, or 78.3%. 7 manufacturers reported payments, led by Gilead at 32.2% of the total. Among internal medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 837 payments — averaging $829.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$223K
- Viiv Healthcare Company$197K
- Janssen Products, LP$123K
- Merck$74K
- Theratechnologies Inc.$74K
- Janssen Scientific Affairs, LLC$2K
- plus $368 from 1 others
Across 13 payments — averaging $54,148 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$704K
What the payments were for
- Consulting fees$39,4386%
- Speaking & faculty fees$543,37178%
- Travel & lodging$89,78513%
- Food & beverage$21,1733%
- Education$2860%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 291 | $223,429 |
| Viiv Healthcare Company | 236 | $197,099 |
| Janssen Products, LP | 127 | $122,980 |
| Merck | 87 | $74,240 |
| Theratechnologies Inc. | 78 | $74,197 |
| Janssen Scientific Affairs, LLC | 5 | $1,739 |
| Johnson & Johnson(2 entities) | 13 | $368 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$694,053 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 496 | $1,901,045 |
| DovatoDolutegravir Sodium/Lamivudine | 90 | $269,916 |
| JulucaDolutegravir/Rilpivirine | 39 | $127,300 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 28 | $120,754 |
| TivicayDolutegravir Sodium | 53 | $118,322 |
| CabenuvaCabotegravir/Rilpivirine | 15 | $99,643 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 23 | $87,759 |
| DescovyEmtricitabine/Tenofov Alafenam | 40 | $86,721 |
| TrulicityDulaglutide | 71 | $82,928 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 18 | $81,165 |
| PrezcobixDarunavir/Cobicistat | 29 | $69,030 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 16 | $62,293 |
| OzempicSemaglutide | 44 | $48,768 |
| PifeltroDoravirine | 25 | $43,156 |
| Isentress HdRaltegravir Potassium | 14 | $27,329 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $223,429 | $2,075,525559 claims |
| Viiv Healthcare CompanyDovato, Juluca, Tivicay, Cabenuva, Triumeq | $197,099 | $677,474213 claims |
| MerckPifeltro, Isentress Hd, Janumet, Janumet Xr | $74,240 | $88,59670 claims |
| Janssen Products, LPSymtuza | $122,980 | $81,16518 claims |
| Johnson & JohnsonPrezcobix | $368 | $69,03029 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Bronx
- Bulent AtacBronx$647K
- Timothy KanterBronx$630K
- Shervin MortazaviBronx$374K
- Elizabeth Jenny-AvitalBronx$185K
- Meyer HalberstamBronx$143K
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.